272152例极高和高骨折风险老年患者的特征与治疗选择
基于2013至2023年巴伐利亚老年医学数据库272152例老年患者数据,评估骨质疏松治疗需求与适用性。超过75%符合特定抗骨质疏松治疗条件,54%为极高骨折风险、符合骨合成代谢治疗,8%至20%存在禁忌证,但多数仍适合治疗。
要点
- 超过75%的老年患者符合特定抗骨质疏松治疗条件,其中54%为极高骨折风险、符合骨合成代谢治疗。
- 极高风险组认知功能(MMSE 23±5分)与日常生活活动能力(ADL 45±20分)评分最低。
- 骨合成代谢治疗禁忌证见于20%的女性和8%的极高风险患者,70%的总体人群无任何特定抗骨质疏松药物禁忌证。
核心结论
- 大多数老年患者处于骨质疏松性骨折极高风险,特征为认知障碍、日常生活活动受限和脆弱性增加。
- 尽管部分患者存在禁忌证,多数仍适合抗骨质疏松尤其是骨合成代谢治疗。
- 及时风险评估和治疗启动至关重要,需要解决相关障碍。
研究设计与样本
- 基于德国巴伐利亚老年医学数据库(GiB-DAT)2013年至2023年272152例参与者的数据分析,平均年龄82±7岁。
- 使用ICD-10和ATC编码评估危险因素和禁忌证,分析高风险与极高风险组比例、特征及特定抗骨质疏松治疗的禁忌证占比。
主要发现
- 超过75%的患者符合特定抗骨质疏松治疗条件,多数(54%)为极高风险、需要骨合成代谢治疗。
- 极高风险组迷你精神状态检查(MMSE)评分为23±5分,日常生活活动(ADL)评分为45±20分,为各组最低。
- 骨合成代谢治疗禁忌证见于20%的女性和8%的全部极高风险患者。
- 70%的总体研究人群无任何特定抗骨质疏松药物禁忌证。
关键数值与推荐
- 德国骨质疏松指南基于可量化的循证危险因素定义高和极高骨折风险,推荐骨合成代谢治疗作为极高风险者的一线治疗。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Our study of 272,152 geriatric patients assessed osteoporosis treatment requirement and eligibility. Over 75% qualified for therapy, with 54% at very high fracture risk, classifying for bone anabolic treatment. Despite contraindications in 8-20%, most were suitable for treatment. Especially in geriatric patients, early risk-assessment and timely intervention are essential. PURPOSE: The German osteoporosis guideline defines high and very high fracture-risk based on quantifiable evidence-based risk-factors, recommending bone anabolic treatment as first-line therapy for the latter. Given age as a major risk factor, we investigated the proportion of geriatric patients with very high fracture risk, their characteristics, and the percentage suitable for bone anabolic treatment considering contraindications. METHODS: Data from the Geriatrics in Bavaria-Database (GiB-DAT, Geriatrie in Bayern Datenbank) included 272,152 participants (mean age 82 ± 7 years) between 2013 and 2023. Risk-factors and contraindications were evaluated using ICD-10- (International Statistical Classification of Diseases) and ATC-codes (Anatomical Therapeutical Chemical Classification). We analyzed the proportion in the high-risk and very high-risk group, their characteristics, and the share with a contraindication for specific anti-osteoporotic treatments. RESULTS: > 75% of the patients qualified for specific anti-osteoporotic treatment, with the majority (54%) at very high-risk requiring bone anabolic treatment. Patients in the very high-risk group had the lowest mini mental status examination (MMSE) (23 ± 5 points) and activities of daily living (ADL) scores (45 ± 20 points). Contraindications for bone anabolic treatments were found in 20% of women and 8% of all very high-risk patients. Seventy percent of the total study population had no contraindication for any specific anti-osteoporotic medications. CONCLUSION: The majority of geriatric patients is at a very high-risk for osteoporotic fractures, characterized by cognitive impairment, ADL limitations, and increased vulnerability. While some patients had contraindications, most were eligible for anti-osteoporotic and particularly bone anabolic treatments. Timely risk-assessment and treatment initiation is crucial and barriers need to be addressed.
引用
- Rippl M, Grupp P, Martini S, et al. Characteristics and treatment options of 272,152 geriatric patients with very high and high fracture risk. Osteoporos Int. 2025. PMID: 40445411. doi:10.1007/s00198-025-07540-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。